How it works.
How it works.
MRD Monitoring in Multiple Myeloma Made Easy.
What it is exactly.
EasyM™ is a non-invasive and highly sensitive, mass spectrometry-based M-protein monitoring test for patients with Multiple Myeloma (MM). EasyM™ identifies the patient’s unique M-protein peptide sequence (a biomarker for MM) and follows this unique sequence to quantify the change in M-protein levels over time.
Applied on peripheral blood, the test can be performed as frequently as needed, providing patients with a more convenient, non-invasive alternative for routine MRD monitoring throughout their treatment journey.
EasyM is a truly personalized, precise monitoring test for patients with Multiple Myeloma (MM) that is non-invasive and highly sensitive. It relies on sequencing the patients’ unique M-protein (a biomarker for MM), and then quantifying the change in M-protein levels over time. It is sensitive enough to detect Multiple Myeloma relapse 10 months earlier than traditional tests. Applied on peripheral blood, the test can be readily performed as frequently as needed providing each patient with better routine monitoring than available conventional testing.
*Preliminary results based on interim data, are subject to change.
Upcoming Conferences.
Sign up to follow our progress with bringing EasyM™ to the Myeloma community.
References
1. Slade M, et al. Blood 2022; 140 (Supplement 1): 4376–4377.